Yiming Luo: Anti-β2GPI GWAS Reveals a Paradox in Thrombotic Mechanisms
Yiming Luo, Rheumatologist and Scientist at Columbia Medicine, shared a post on X:
”Our anti-β2GPI GWAS paper is now out! We found a paradox and a plausible explanation.
Our human genetics work re-capitulated the established model that Domain V binding to phospholipid is essential for anti-β2GPI-mediated thrombosis.
These findings have clinical application potentials, but large patient cohort studies are necessary to elucidate.”
ACR Journals shared a post on X about a recent article by Christophe Lalaurie et al., adding:
”A coding variant in APOH was associated with higher anti-β2-glycoprotein I antibody levels but lower venous thromboembolism risk.
Genetic and structural analyses suggest that altered phospholipid binding and epitope exposure may explain this paradox.
Molecular dynamics simulations of wild-type and W335S β2GPI (APOH) in a representative linear conformation (J-shape 2).”
Title: A Coding Single Nucleotide Polymorphism in β2-Glycoprotein I (APOH) is Associated with Increased Autoantibody Levels but Reduced Venous Thromboembolism Risk
Authors: Christophe Lalaurie, Lili Liu, Atlas Khan, Chen Wang, Stephen S. Rich, R. Graham Barr, Elana J. Bernstein, Krzysztof Kiryluk, Thomas McDonnell, Yiming Luo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A